Journal: MedComm

Article Title: Ipriflavone From Aquilaria malaccensis Lam. Exosome‐Like Nanoparticles Targets Prolyl Hydroxylase Domain Protein 2 (PHD2) to Enhance Hypoxia‐Inducible Factor‐α (HIF‐α) Hydroxylation Thereby Alleviating Hypoxia‐Induced Gastrointestinal Mucosal Ferroptosis

doi: 10.1002/mco2.70722

Figure Lengend Snippet: Oral administration of AELNs ameliorated gastric and small intestinal mucosal ferroptosis caused by hypoxia in mice. The mice were housed in a vented hypoxic chamber for 3 days ( n = 10 mice in each group). They received PBS or AELNs (1 × 10 5 particles) via oral gavage on Day 1 and were euthanized on Day 3. Representative photographs showing the microstructures of the murine gastric (A) and small intestinal mucosal cells (B) under transmission electron microscopy (TEM). The red arrows indicate shrunken mitochondria (scale bar: overview, 1 µm; inset, 500 nm). Quantification of Fe 2+ , reactive oxygen species (ROS), lipid peroxidation (LPO), and 4‐hydroxynonenal (4‐HNE) of the gastric (C) and small intestinal (D) mucosa ( n = 10). Western blot analysis of the indicated protein levels in the gastric (E) and small intestinal (F) mucosa assessed by Western blot. (G) Cytokines in the gastric (upper) and small intestinal (lower) mucosa ( n = 10). Error bars indicate mean ± SEM. One‐way ANOVA: * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001; ns, not significant.

Article Snippet: ROS, 4‐HNE, and LPO levels were measured using kits from Elabscience (ROS, E‐BC‐K138‐F; 4‐HNE, E‐EL‐0128c; LPO, E‐BC‐K176‐M; Wuhan, Hubei, China).

Techniques: Transmission Assay, Electron Microscopy, Western Blot

Journal: eBioMedicine

Article Title: Multi-omics identifies oxidative stress, prothrombotic pathways, and lactoperoxidase variants as key factors in COVID-19 severity

doi: 10.1016/j.ebiom.2025.106111

Figure Lengend Snippet: Genetic and expression evidence of the LPO lactoperoxidase gene in COVID-19 severity. (A) Lollipop diagram of LPO showing the 6 coding variants identified in our COVID-19 patient cohort (green = missense, black = truncating). The diagram was obtained using the MutationMapper tool on the cBioPortal for Cancer Genomics ( https://www.cbioportal.org/mutation_mapper ). (B) Normalized LPO mRNA expression levels in patients admitted to ICU and those hospitalised, as retrieved from RNA-seq data on patients' PBMCs. Each dot represents an individual sample; boxplots show the median, interquartile range, and distribution. (C) Meta-analysis of the association between the common rs77996252 SNP in LPO and COVID-19 severity in the RGC database. The Forest plot visualises the individual study ORs, 95% CIs, and the pooled OR. The x-axis is displayed on a log10 scale. Each study's OR, 95% CI, and p-value were displayed alongside the plot. (D) Meta-analysis of the association between rare variants in LPO and COVID-19 severity. The Forest plot visualises the individual study ORs, 95% CIs, and the pooled OR. The x-axis is displayed on a log10 scale. Each study's OR, 95% CI, and p-value were displayed alongside the plot. Data include European cohorts (UK Biobank and Geisinger Health System) from the RGC database and our own Italian cohort. (E) Differential LPO expression in disease vs healthy individuals by protein extension assay. Data were retrieved from the Human Protein Atlas. Each dot represents a disease. The x-axis indicates the p-value of significance whereas the y-axis reports the log2(fold-change) in the expression of LPO protein in diseased patients vs healthy controls.

Article Snippet: Finally, to better understand whether and how LPO levels are altered in COVID-19 or other disease conditions, we explored publicly available data on LPO protein levels in blood from the Human Protein Atlas ( https://www.proteinatlas.org/ENSG00000167419-LPO/blood ).

Techniques: Expressing, Mutagenesis, RNA Sequencing